No.	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
1	14/SC/1161	155743	Prospective, single-arm, multi-centre, observational registry to further validate safety and efficacy of the ultimaster des system in unselected patients representing everyday clinical practice.	Number Agreed	50	50	Date Agreed	31/05/2018	221	03/05/2018	221	Recruitment Finished
2	14/SC/1366	135118	EPOCH: Protocol TS-102: A phase 3 clinical trial evaluating Therasphere in patients with metastatic colorectal carcinoma of the liver who have failed first line chemotherapy	Number Agreed	3	3	Date Agreed	12/10/2018	3	12/10/2018	4	Recruitment Finished
3	15/NW/0868	188121	A Phase 3 study of Efficacy, Safety and Tolerability of Chronocort® compared with Standard Glucocorticoid Replacement Therapy in the treatment of Congenital Adrenal Hyperplasia.	Number Agreed	7	7	Date Agreed	31/01/2018	10	31/01/2018	10	Recruitment Finished
4	15/WM/0056	159740	Development of a MR Scanner Capable of Being Sited in a Neonatal Intensive Care Unit	Range Agreed	35	60	Date Agreed	24/02/2018	54	24/02/2018	54	Recruitment Finished
5	16/EM/0193	190690	A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS): The dal-GenE trial.	Number Agreed	5	5	Date Agreed	30/11/2018	6	15/12/2018	6	Recruitment Finished
6	16/EM/0278	208188	A Phase III extension study of efficacy, safety and tolerability of Chronocort® in the treatment of congenital adrenal hyperplasia.	Range Agreed	1	7	Date Agreed	12/03/2018	10	12/03/2018	10	Recruitment Finished
7	16/LO/1697	212844	A Phase III randomised, controlled clinical trial of Pembrolizumab with or without platinum-based combination chemotherapy versus chemotherapy in subjects with advanced or metastatic urothelial carcinoma [KEYNOTE 361]	Number Agreed	3	3	Date Agreed	30/04/2018	4	31/05/2018	4	Recruitment Finished

8	16/LO/1794	213087	Safety, tolerability, and pharmacokinetics study of single and multiple subcutaneous doses of turoctocog alfa pegol in patients with haemophilia A	Number Agreed	2	2	Date Agreed	01/08/2018	2	01/08/2018	2	Recruitment Finished
9	16/NW/0242	193020	A Phase 1, randomised, open-label, 2-cohort, cross-over study to evaluate the pharmacokinetics, safety, and tolerability of a native oral testosterone formulation (DITEST) in the fed and fasted state and compared to testosterone undecanoate in adult men with primary or secondary hypogonadism	Number Agreed	24	24	Date Agreed	30/09/2018	25	30/09/2018	25	Recruitment Finished
10	16/SC/0391	208610	A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis.	Range Agreed	4	21	Date Agreed	01/05/2019	19	16/04/2018	19	Recruitment Finished
11	16/SC/0484	208568	An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination with Ipilimumab versus Extreme Study Regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) CheckMate 651	Range Agreed	4	8	Date Agreed	19/12/2018	5	27/11/2018	5	Recruitment Finished
12	16/WM/0359	211812	A Phase 2/3 Multi-center Study to Evaluate the Safety and Efficacy of Blinatumomab in Subjects with Relapsed/Refractory Aggressive B-Cell Non Hodgkin Lymphoma.	Range Agreed	2	5	Date Agreed	30/05/2020	4	16/01/2018	4	Recruitment Finished
13	16/YH/0024	196244	A Phase 1 Placebo-Controlled, Single and Multiple Ascending Dose Study to EvaluateThe Safety, Tolerability, and Pharmacokinetics of BIIB067 Administered to Adult Subjects with Amyotrophic Lateral Sclerosis.	Number Agreed	6	6	Date Agreed	30/06/2019	7	30/06/2018	7	Recruitment Finished

14	16/YH/0450	213782	Study Investigating the Safety and Efficacy of Blinatumomab After Frontline R-Chemotherapy in Adult Subjects With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma (DLBCL)	Range Agreed	2	5	Date Agreed	30/06/2018	3	04/05/2018	3	Recruitment Finished
15	16/YH/0454	211679	A prospective multi-centre observational study to evaluate the capabilities of a portable magnetocardiograph (MCG) device to rule-out acute coronary syndrome (ACS) in patients who present to the emergency department with chest pain symptoms consistent with ACS.	Number Agreed	175	175	Date Agreed	30/04/2018	175	30/04/2018	175	Recruitment Finished
16	17/EE/0297	225586	A Single-Arm, Multicentre Phase IIIB Clinical Trial to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients with Inhibitors [STASEY]	Range Agreed	1	2	Date Agreed	31/10/2018	2	31/10/2018	2	Recruitment Finished
17	17/EM/0361	234065	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of BIIB033 as an Add-On Therapy to Anti-Inflammatory Disease-Modifying Therapies	Number Agreed	2	2	Date Agreed	30/06/2019	2	30/08/2018	2	Recruitment Finished
18	17/NW/0374	226708	A Multi-Centre, Randomised, Open-Label, Controlled Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients with Inhibitors	Number Agreed	1	1	Date Agreed	28/12/2018	1	28/12/2018	1	Recruitment Finished
19	17/YH/0388	235066	A multi-center, double-blind, randomized, placebo-controlled study to assess the pharmacodynamics, pharmacokinetics, tolerability, and safety of a single subcutaneous injection of ACT-246475 in adults with stable coronary artery disease	Number Agreed	13	13	Date Agreed	31/08/2018	66	31/08/2018	66	Recruitment Finished
20	18/EE/0067	242431	Safety and Efficacy of turoctocog alfa pegol (N8-GP) in Prophylaxis and Treatment of Bleeds in Previously N8-GP Treated Patients with Severe Haemophilia A [Pathfinder 8]	Number Agreed	2	2	Date Agreed	03/12/2018	2	03/12/2018	2	Recruitment Finished

21	18/NW/0008	231939	A Randomized, Observer Blind, Phase 3 Trial to Investigate the Immunogenicity and Safety of the Co-administration of a Subcutaneous Tetravalent Dengue Vaccine Candidate (TDV) and an Intramuscular Hepatitis A Virus (Inactivated) vaccine in Healthy Subjects Aged 18 to 60 Years in Non-endemic Countries for Dengue	Number Agreed	5	5	Date Agreed	14/09/2018	10	14/09/2018	10	Recruitment Finished
22	18/SC/0139	240580	A Phase 3, INterVentional, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of DCC-2618 In Patients with Advanced c-KIT/PDGFRA Gastrointestinal Stromal TUmorS who have Received Prior Treatment with Imatinib, Sunitinib, and/or Regorafenib	Range Agreed	0	2	Date Agreed	30/09/2018	1	16/11/2018	2	Recruitment Finished
23	18/SC/0210	239572	A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study To Evaluate The Efficacy And Safety Of Pf-04965842 Monotherapy In Subjects Aged 12 Years And Older, With Moderate To Severe Atopic Dermatitis	Range Agreed	1	2	Date Agreed	30/11/2018	2	30/11/2018	2	Recruitment Finished
24	12/YH/0498	102641	An Open, Phase I, Exploratory Study of MTL-005 Radiosensitization in Patients With Advanced Carcinoma of the Head and Neck: Part 1 to Evaluate Safety in a Dose Escalation Design in Patients Indicated for Palliative Radiotherapy, Part 2 to Evaluate Safety and Efficacy in a Dose-Escalation Design in Patients Indicated for Cisplatin Chemoradiotherapy - MOREX	Number Agreed	7	7	Date Agreed	20/03/2018	4	20/03/2018	4	Recruitment Finished
25	15/EM/0179	177000	Understanding Outcomes with the EMBLEM S-ICD in Primary Prevention Patients with Low Ejection Fraction UNTOUCHED	Range Agreed	7	50	Date Agreed	31/12/2019	6	27/02/2018	6	Recruitment Finished

26	15/YH/0117	173811	A prospective, multicenter, single-arm, open-label, Phase 4 study to evaluate the effects of macitentan on Right vEntricular remodeling in Pulmonary ArterIal hypeRtension assessed by cardiac magnetic resonance imaging - REPAIR	Range Agreed	0	2	Date Agreed	30/06/2018	0	19/07/2018	0	Recruitment Finished
27	16/EE/0040	196164	Randomized, Multicenter, Multiple Ascending-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A Administered by Subcutaneous Injection in Patients with Non Healing Neuropathic Diabetic Foot Ulcers.	Number Agreed	1	1	Date Agreed	24/02/2018	0	08/01/2018	0	Recruitment Finished
28	16/EM/0376	211430	A 12-week, randomized, multi-center, double-blind, placebo-controlled, 3-arm, parallel-group, phase 3 trial to evaluate the efficacy and safety of 2 doses of AQX-1125 targeting the SHIP1 pathway in subjects with interstitial cystitits/bladder pain syndrome followed by a 2-arm, 14 or 40 week open label extension	Number Agreed	4	4	Date Agreed	31/03/2018	1	15/02/2018	1	Recruitment Finished
29	16/EM/0384	182787	CV 185316: An Open-label, 2x2 Fractorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients with Atrial Fibrilation and Acute Coronary Syndrome or Percutaneous Coronary Intervention	Number Agreed	8	8	Date Agreed	31/05/2018	4	10/04/2018	4	Recruitment Finished
30	16/EM/0436	213166	Single arm study of ALXN1210 in complement inhibitor treatment-naïve adult and adolescent patients with Atypical Hemolytic Uremic Syndrome (aHUS)	Range Agreed	0	1	Date Agreed	31/12/2018	0	25/05/2018	0	Recruitment Finished

31	16/EM/0443	208418	STEM – A multicentre Phase 2 study of SFX-01 treatment and evaluation in patients with Estrogen Receptor (ER) positive and Human Epidermal Growth Factor Receptor 2 (HER2) negative metastatic breast cancer progressing on either an Aromatase Inhibitor (AI) or Tamoxifen or Fulvestrant	Range Agreed	4	10	Date Agreed	24/07/2018	0	24/07/2018	0	Recruitment Finished
32	16/LO/1138	207606	A Phase II, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of abituzumab in subjects with systemic sclerosis-associated interstitial lung disease (SSc-ILD).	Number Agreed	1	1	Date Agreed	30/11/2018	0	17/01/2018	0	Withdrawn By Sponsor
33	16/NW/0606	211110	A Phase II single-arm, open-label monotherapy clinical trial of Pembrolizumab (MK-3475) in locally advanced/metastatic renal cell carcinoma (mRCC) (KEYNOTE-427)	Number Agreed	4	4	Date Agreed	20/03/2020	0	24/04/2018	0	Withdrawn By Sponsor
34	16/SC/0653	215441	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy	Number Agreed	4	4	Date Agreed	31/08/2018	0	27/04/2018	0	Withdrawn By Sponsor
35	16/WM/0317	206807	RESTORE-BRAIN: Randomised efficacy and safety trial with oral S44819 after recent ischemic cerebral event. An international, multi-centre, randomized, double-blind, placebo controlled phase II study	Number Agreed	4	4	Date Agreed	31/12/2018	1	15/11/2018	1	Recruitment Finished
36	16/YH/0186	200765	A phase 4 double-blind, randomized, placebo-controlled, multi-center study to evaluate the efficacy, safety and tolerability of mirabegron in men with overactive bladder (OAB) symptoms while taking the alpha-blocker tamsulosin hydrochloride for lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH).	Number Agreed	8	8	Date Agreed	18/04/2018	0	18/04/2018	0	Recruitment Finished

37	17/EE/0205	224373	A Phase I Open-Label Dose Escalation Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care Chemotherapy for the Treatment of Multiple Myeloma	Range Agreed	2	4	Date Agreed	03/12/2018	1	30/11/2018	1	Withdrawn By Sponsor
38	17/LO/0169	214075	Effect of MD1003 in progressive multiple sclerosis: a randomized double blind placebo controlled study	Number Agreed	4	4	Date Agreed	31/05/2018	0	27/04/2018	0	Recruitment Finished
39	17/LO/0380	218003	A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of Crenezumab in patients with prodromal to mild Alzheimer's disease - Cread 2	Number Agreed	6	6	Date Agreed	30/03/2018	0	05/04/2018	0	Withdrawn By Sponsor
40	17/LO/1147	222154	A Randomised, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy and safety of tralokinumab monotherapy in subjects with moderate-to-severe atopic dermatitis who are candidates for systemic therapy	Number Agreed	6	6	Date Agreed	31/05/2018	4	23/03/2018	4	Recruitment Finished
41	17/NE/0115	218417	Multi-center, international, double-blind, two-arm, randomized, placebo-controlled phase II trial of pirfenidone in patients with unclassifiable progressive fibrosing ILD	Range Agreed	3	4	Date Agreed	23/04/2018	1	26/04/2018	1	Recruitment Finished
42	17/NE/0377	233847	prospective, randomized, double blind, placebo-controlled study to reduce incidence of pre-dialysis hyperkalemia with Sodium Zirconium Cyclosilicate (DIALIZE)	Number Agreed	3	3	Date Agreed	13/09/2018	0	14/08/2018	0	Recruitment Finished
43	17/NW/0180	220257	A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy	Range Agreed	0	2	Date Agreed	30/09/2018	0	08/08/2018	0	Recruitment Finished
44	17/SC/0023	220276	A Phase 2 study to investigate the efficacy, safety, and tolerability of six weeks treatment with V565 in subjects with active Crohn's disease	Range Agreed	1	2	Date Agreed	31/12/2018	0	21/12/2018	0	Recruitment Finished

45	17/YH/0390	233236	EFC14867 – A 26-week Randomised, Double-blind, Controlled, Parallel-group, Multicentre Study to Evaluate the Efficacy and Safety of Sotagliflozin compared to Empagliflozin, and Placebo in Patients with Type 2 Diabetes Who Have Inadequate Glycaemic Control on Dipeptidyl Peptidase 4 Inhibitor (DPP4(i)) With or Without Metformin	Number Agreed	5	5	Date Agreed	30/11/2018	0	14/09/2018	0	Recruitment Finished
46	18/EM/0027	235145	A dose-ranging study of intravitreal OPT-302 in combination with ranibizumab, compared with ranibizumab alone, in participants with neovascular age-related macular degeneration (wet AMD)	Number Agreed	5	5	Date Agreed	30/11/2018	0	19/11/2018	0	Recruitment Finished